News

Public · Published

QURE: AMT-130 advances toward a 2027 decision, backed by $768.4M in cash and investments

UniQure's AMT-130 received FDA Priority Review, with a decision date set for May 1, 2027. The company is advancing confirmatory-trial and launch preparations. Q3 revenue was $5.2 million, and cash and investments totaled $768.4 million, which the article says provides runway into 2030.

Published:

Updated:

What happened

UniQure’s AMT-130 received FDA Priority Review, with a decision date set for May 1, 2027. The company is advancing confirmatory-trial and launch preparations. Q3 revenue was $5.2 million, and cash and investments totaled $768.4 million, which the article says provides runway into 2030.

Confirmed

Global impact / market context

The review date gives investors a defined regulatory milestone, while trial and launch preparations could require spending before any decision. The reported cash and investments may help fund those activities, but the article does not specify their costs or whether approval will follow.

Analyst inference

The article links AMT-130’s regulatory progress with UniQure’s financial capacity: $5.2 million in Q3 revenue and $768.4 million in cash and investments. That balance is described as funding operations into 2030, but no spending forecast or product revenue outlook is provided.

Confirmed

What to watch

  1. Watch for updates on the confirmatory trial, including its progress and any details about what evidence regulators will require before the May 1, 2027 decision. Analyst inference
  2. Track whether launch preparations advance and how much they cost; the article confirms preparation activity but gives no launch spending estimate or expected sales. Analyst inference
  3. Compare future cash and investment totals with operating needs, since the article says current funds provide runway into 2030 but does not detail cash use. Analyst inference

Evidence

  • Original source link unavailable